港股异动 | 复宏汉霖(2696.HK)高开5.54% 抗S1全人源单克隆中和抗体HLX70的临床试验申请获FDA批准
格隆汇10月8日丨复宏汉霖(2696.HK)高开5.54%,报48.6港元,最新总市值264亿港元。复宏汉霖近日发公告称,新冠病毒中和抗体HLX70针对新冠病毒肺炎、新冠病毒引起的急性呼吸窘迫综合征(ARDS)或多重器官衰竭等适应症的新药临床试验申请,获美国食品药品监督管理局(FDA)批准。HLX70于中国境内(不包括港澳台地区)处于临床前研究阶段。截至公告日,于全球范围内尚无新冠肺炎抗体药物获批上市。野村曾发报告称,将公司2020至2022年的收入预测分别上调至9.35亿、25.57亿及38.39亿元人民币,维持“买入”评级,目标价由52.4港元上调至76.7港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.